- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/18 - Aralkyl radicals
Patent holdings for IPC class C07D 217/18
Total number of patents in this class: 63
10-year publication summary
|
1
|
4
|
8
|
1
|
3
|
5
|
4
|
1
|
8
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Actelion Pharmaceuticals Ltd | 492 |
4 |
| Intervet Inc. | 927 |
3 |
| The Scripps Research Institute | 1342 |
3 |
| Cytosinlab Therapeutics Co., Ltd. | 20 |
3 |
| Novartis AG | 10224 |
2 |
| The Board of Trustees of the Leland Stanford Junior University | 6668 |
2 |
| China State Institute of Pharmaceutical Industry | 21 |
2 |
| Shanghai Institute of Pharmaceutical Industry | 127 |
2 |
| Taisho Pharmaceutical Co., Ltd. | 851 |
2 |
| Zentiva k.s. | 566 |
2 |
| SpecGx LLC | 186 |
2 |
| Huaqiao University | 81 |
2 |
| Jubilant Epicore LLC | 5 |
2 |
| Shanghai Zhimeng Biopharma Inc. | 34 |
2 |
| Dice Molecules Sv, Inc. | 12 |
2 |
| Bayecao Health Industry Research Institute (Xiamen) Co., Ltd. | 2 |
2 |
| Bristol-myers Squibb Company | 4747 |
1 |
| Samsung Display Co., Ltd. | 38721 |
1 |
| BASF SE | 21318 |
1 |
| Boehringer Ingelheim International GmbH | 4487 |
1 |
| Other owners | 22 |